All In Biotech

Drug Trial Radar · NCT06542874

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 448 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

448

Actual

Start

Aug 7, 2024

Primary completion

Oct 1, 2025

Study completion Oct 24, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Conditions

  • Type 2 Diabetes (T2D)

Interventions

  • NNC0487-0111 subcutanousDrug

    NNC0487-0111 administered subcutanously (under the skin)

  • Placebo (NNC0487-0111 subcutanous)Drug

    NNC0487-0111 placebo administered subcutanously (under the skin)

  • NNC0487-0111 oralDrug

    NNC0487-0111 administered orally (in the mouth)

  • Placebo (NNC0487-0111 oral)Drug

    NNC0487-0111 placebo administered orally (in the mouth)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: From baseline (week 0) to end of treatment (week 36)

Locations

137 sites in 11 countries. Site status is shown where the registry gives one.

  • Uni of Alabama at Birmingham

    Birmingham, Alabama

  • Velocity Clin Research LA

    Los Angeles, California

  • Southern Cal Clinical Research

    Santa Ana, California

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Fleming Island Ctr for Clin Res

    Fleming Island, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Florida Inst For Clin Res

    Orlando, Florida

  • Florida Institute for Clinical research

    Orlando, Florida

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas

  • Advanced Internal Medicine, PLLC

    Paducah, Kentucky

  • Medstar Research Institute_Hyattsville

    Hyattsville, Maryland

  • MD Medical Research

    Oxon Hill, Maryland

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • ActivMed Practice & Research LLC

    Methuen, Massachusetts

  • Arcturus HC PLC Troy Med Res

    Troy, Michigan

  • Arcturus Healthcare, PLC

    Troy, Michigan

  • Clinical Research Professionals

    Chesterfield, Missouri

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • AMC Community Endocrinology

    Albany, New York

  • Centricity Rsrch MHCity Multi

    Morehead City, North Carolina

  • Piedmont Healthcare/Research

    Statesville, North Carolina

  • Lillestol Research LLC

    Fargo, North Dakota

  • Plains Clinical Research Center, LLC_Fargo

    Fargo, North Dakota

  • Alliance for Multispec Res

    Norman, Oklahoma

  • Jefferson Endocrinology Assocs

    Philadelphia, Pennsylvania

  • Preferred Primary Care Physicians_Pittsburgh

    Pittsburgh, Pennsylvania

  • Health Concepts

    Rapid City, South Dakota

  • Holston Medical Group

    Kingsport, Tennessee

  • Clinical Research Associates

    Nashville, Tennessee

  • MidState Endocrine Associates

    Nashville, Tennessee

  • Velocity Clinical Res-Dallas

    Dallas, Texas

  • Victorium Clinical Research

    Houston, Texas

  • Synergy Groups Medical

    Houston, Texas

  • PlanIt Research, PLLC

    Houston, Texas

  • Radiance Clinical Research

    Lampasas, Texas

  • Tekton Research

    McKinney, Texas

  • Hillcrest Family Health Center

    Waco, Texas

  • Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.

    Kyustendil, Bulgaria

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.